Cover Image

Nebenwirkungsmanagement in der Immunonkologie

<p>The immune oncological treatment approach uses immune checkpoint inhibitors to prevent tumor cells from shutting down the immune system, and thus from escaping immune response. Following the clinical success of immune checkpoint inhibitors, the number of approved immune oncological therapie...

Full description

Saved in:
Bibliographic Details
Main Authors: Reinmuth, Niels (Author) , Bitzer, Michael (Author) , Deschler-Baier, Barbara (Author) , Fischer, Jürgen (Author) , Kuon, Jonas (Author) , Leipe, Jan (Author) , Rawluk, Justyna (Author) , Schulz, Christian (Author) , Heußel, Claus Peter (Author) , Schultheiß, Michael (Author)
Format: Article (Journal)
Language:German
Published: 2019
In: Deutsche medizinische Wochenschrift
Year: 2019, Volume: 144, Issue: 05, Pages: 346-353
ISSN:1439-4413
DOI:10.1055/a-0739-8194
Online Access:Verlag, Volltext: https://doi.org/10.1055/a-0739-8194
Verlag, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-0739-8194
Get full text
Author Notes:Niels Reinmuth, Michael Bitzer, Barbara Deschler-Baier, Jürgen R. Fischer, Jonas Kuon, Jan Leipe, Justyna Rawluk, Christian Schulz, Claus Peter Heußel, Michael Schultheiß
Description
Summary:<p>The immune oncological treatment approach uses immune checkpoint inhibitors to prevent tumor cells from shutting down the immune system, and thus from escaping immune response. Following the clinical success of immune checkpoint inhibitors, the number of approved immune oncological therapies continues to increase. Response rates and overall survival with anti-PD-1/PD-L1 and CTLA-4 blockade could be further improved by combining both treatment approaches. However, checkpoint inhibition is associated with a unique spectrum of side effects termed immune-related adverse events. These typically occur 3 to 6 months after treatment start and resolve with adequate management procedures if detected early on. Therefore, profound patient education, sensitizing and monitoring are mandatory. We describe in this article selected frequent and rare adverse events that are clinically relevant. Furthermore, using case reports, interdisciplinary experts share their practice-based experience in the management of frequent pneumonic, endocrine, and gastro-intestinal immune-related adverse events.</p>
Item Description:Gesehen am 09.05.2019
Physical Description:Online Resource
ISSN:1439-4413
DOI:10.1055/a-0739-8194

Similar Items